Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
08:01pm, Thursday, 15'th Feb 2024
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Thursday, 15'th Feb 2024
AtriCure (ATRC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.09 per share a year ago.
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
04:01pm, Thursday, 15'th Feb 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
Seeking Clues to AtriCure (ATRC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:21am, Monday, 12'th Feb 2024
Get a deeper insight into the potential performance of AtriCure (ATRC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference
08:00am, Thursday, 25'th Jan 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure Appoints Shlomi Nachman to the Board of Directors
08:00am, Thursday, 04'th Jan 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 20'th Dec 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain
Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should Know
11:17am, Wednesday, 15'th Nov 2023
The consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
08:00am, Wednesday, 15'th Nov 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain
AtriCure Releases 2023 ESG Report
08:00am, Tuesday, 14'th Nov 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure: Appeal Lures For This Cure
02:59pm, Friday, 10'th Nov 2023
AtriCure has seen solid revenue growth but needs more operating leverage to improve its bottom line. The company's shares have experienced a meaningful pullback from their highs in June. Despite conti
All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy
01:32pm, Monday, 06'th Nov 2023
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript
10:58pm, Wednesday, 01'st Nov 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych – Gilmartin Group, Investor Relations Mike Carrel – President and Chief
AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to Say
07:32pm, Wednesday, 01'st Nov 2023
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall St
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
09:23pm, Tuesday, 25'th Jul 2023
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare t
